AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
Want to see ANTX full AI Analyst Report?
Total Valuation
AN2 Therapeutics, Inc. has a market cap or net worth of $161.35M. The enterprise value is $72.29M.
Market Cap$161.35M
Enterprise Value$72.29M
Share Statistics
AN2 Therapeutics, Inc. has 36,016,163 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding36,016,163
Owned by Insiders26.51%
Owned by Institutions41.18%
Financial Efficiency
AN2 Therapeutics, Inc.’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -71.59%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-71.59%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee0.00
Profits Per Employee-1.60M
Employee Count22
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of AN2 Therapeutics, Inc. is ―. AN2 Therapeutics, Inc.’s PEG ratio is 0.03.
PE Ratio―
PS Ratio0.00
PB Ratio0.65
Price to Fair Value0.65
Price to FCF-1.15
Price to Operating Cash Flow-5.00
PEG Ratio0.03
Income Statement
In the last 12 months, AN2 Therapeutics, Inc. had revenue of 0.00 and earned -35.17M in profits. Earnings per share was -1.16.
Revenue0.00
Gross Profit0.00
Operating Income-38.11M
Pretax Income-35.17M
Net Income-35.17M
EBITDA-38.11M
Earnings Per Share (EPS)-1.16
Cash Flow
In the last 12 months, operating cash flow was -31.28M and capital expenditures 0.00, giving a free cash flow of -31.28M billion.
Operating Cash Flow-31.28M
Free Cash Flow-31.28M
Free Cash Flow per Share-0.87
Dividends & Yields
AN2 Therapeutics, Inc. pays an annual dividend of $0.656, resulting in a dividend yield of ―
Dividend Per Share$0.656
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.14
52-Week Price Change292.31%
50-Day Moving Average4.12
200-Day Moving Average1.93
Relative Strength Index (RSI)55.94
Average Volume (3m)73.31K
Important Dates
AN2 Therapeutics, Inc. upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 11, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
AN2 Therapeutics, Inc. as a current ratio of 6.87, with Debt / Equity ratio of 0.00%
Current Ratio6.87
Quick Ratio6.87
Debt to Market Cap0.00
Net Debt to EBITDA0.52
Interest Coverage Ratio0.00
Taxes
In the past 12 months, AN2 Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
AN2 Therapeutics, Inc. EV to EBITDA ratio is -0.38, with an EV/FCF ratio of -0.49.
EV to Sales0.00
EV to EBITDA-0.38
EV to Free Cash Flow-0.49
EV to Operating Cash Flow-0.49
Balance Sheet
AN2 Therapeutics, Inc. has $85.29M in cash and marketable securities with $0.00 in debt, giving a net cash position of $85.29M billion.
Cash & Marketable Securities$85.29M
Total Debt$0.00
Net Cash$85.29M
Net Cash Per Share$2.37
Tangible Book Value Per Share$1.76
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for AN2 Therapeutics, Inc. is $9.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$9.00
Price Target Upside689.47% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast27.21%